This is the authors' abstract. We don't add key points for this paper.
A clinical states model to mark the progression of prostate cancer from diagnosis to death is proposed. The model includes a representation of both the natural and treated history of the disease and provides a framework to assess and reassess prognosis over time. The states are clearly defined, few in number, and mutually exclusive. Incorporated into a clinical data base, they can be used to monitor individual patients or a cohort of patients and to facilitate clinical decision making based on the risk of disease progression. Built into the data base framework are probabilistic models that can be used to predict the likelihood of reaching any one of the advanced clinical states. The determination of risk to a progressing state is derived from the different trajectories to that state, the current clinical state, and prognostic factors (clinical or biologic) within the current state that are predictive of disease progression.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Scher et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: